Paths Forward: Venezuela’s Leadership & Rare Disease Regulation 1/8/26

Squawk Pod

CNBC

Business News, News, Investing, Business

4.2 • 543 Ratings

🗓️ 8 January 2026

⏱️ 32 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Pulitzer Prize-winning NYTimes Opinion columnist Tom Friedman shares his perspective on the United States’ indefinite involvement in Venezuela. He warns that without a pathway toward functioning democracy, the country’s “mafia leadership” may remain in place. President Trump is speaking out against defense company stock dividends and buybacks. Plus, Becky Quick shares her personal connection to CNBC’s newest initiative, CNBC Cures. In a conversation with former FDA Commissioner Dr. Scott Gottlieb, she discusses the scale of rare diseases and the regulatory hurdles that impact treatments for diagnoses like that of her own daughter, Kaylie. Join us in advancing awareness and understanding of rare diseases. Listen to The Path with Becky Quick, and visit CNBC.com/Cures to access clips, resources, or to sign up for our weekly newsletter. Tom Friedman - 13:05 Dr. Scott Gottlieb - 26:06 In this episode: Becky Quick, @BeckyQuick Joe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkin Katie Kramer, @Kramer_Katie

Transcript

Click on a timestamp to play from that location

0:00.0	Bring in show music, please.
0:03.0	Hi, I'm CNBC producer Katie Kramer.
0:07.0	Today on Squawk Pot.
0:09.0	The uncertain road ahead for Venezuela,
0:12.0	including the United States indefinite involvement in the country,
0:15.0	both in industry and in government.
0:18.0	This is state-sponsored capitalism.
0:20.0	But now, but it's down in Venezuela.
0:21.6	Yeah, but it's here too.
0:23.6	The Pulitzer Prize winning New York Times columnist Tom Friedman.
0:26.6	Changing a country of 28 million people by remote control and just focusing on oil, I saw that play in Libya.
0:34.6	It ended really badly.
0:36.6	And President Trump is speaking out against defense company buybacks.
0:41.3	I don't know if they need chastising or government intervention to tell them how to spend
0:47.4	the law. Look, what I will say is that in an industry like defense, where it is so reliant on
0:52.9	spending. Maybe they should have more of a say.
0:56.0	Plus, a special conversation as we launched CNBC's newest project, CNBC Cures.
1:02.0	One in 10 Americans affected, therapies disparate and slow to reach patients.
1:06.0	It is a deep and personal dive into rare disease.
1:10.0	Former FDA Commissioner, Dr. Scott Gottlieb. Regulation is a deep and personal dive into rare disease. Former FDA Commissioner Dr. Scott Gottlieb.
1:13.0	Regulation is a roadblock here because it's still hard to do the so-called end-of-one trials.
1:18.3	I think while the FDA has opened up a pathway to this,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from CNBC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of CNBC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.